These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23057615)

  • 1. A new approach to counteract bacteria resistance: a comparative study between moxifloxacin and a new moxifloxacin derivative in different model systems of bacterial membrane.
    Lopes SC; Ribeiro C; Gameiro P
    Chem Biol Drug Des; 2013 Feb; 81(2):265-74. PubMed ID: 23057615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facilitated permeation of antibiotics across membrane channels--interaction of the quinolone moxifloxacin with the OmpF channel.
    Mach T; Neves P; Spiga E; Weingart H; Winterhalter M; Ruggerone P; Ceccarelli M; Gameiro P
    J Am Chem Soc; 2008 Oct; 130(40):13301-9. PubMed ID: 18788798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin metalloantibiotic: an effective antibiotic with an influx route strongly dependent on lipid interaction?
    Ferreira M; Gameiro P
    J Membr Biol; 2015 Feb; 248(1):125-36. PubMed ID: 25378125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into the translocation route of enrofloxacin and its metalloantibiotics.
    Ribeiro C; Lopes SC; Gameiro P
    J Membr Biol; 2011 Jun; 241(3):117-25. PubMed ID: 21584680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoroquinolone Metalloantibiotics to Bypass Antimicrobial Resistance Mechanisms: Decreased Permeation through Porins.
    Ferreira M; Sousa CF; Gameiro P
    Membranes (Basel); 2020 Dec; 11(1):. PubMed ID: 33375018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the permeation of fluoroquinolone metalloantibiotics across outer membrane porins by combining molecular dynamics simulations and a porin-mimetic in vitro model.
    Sousa CF; Coimbra JTS; Richter R; Morais-Cabral JH; Ramos MJ; Lehr CM; Fernandes PA; Gameiro P
    Biochim Biophys Acta Biomembr; 2022 Mar; 1864(3):183838. PubMed ID: 34896074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
    Singh R; Ledesma KR; Chang KT; Hou JG; Prince RA; Tam VH
    J Antimicrob Chemother; 2009 Sep; 64(3):556-62. PubMed ID: 19589810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term potency, sterility, and stability of vancomycin, ceftazidime, and moxifloxacin for treatment of bacterial endophthalmitis.
    Mehta S; Armstrong BK; Kim SJ; Toma H; West JN; Yin H; Lu P; Wayman LL; Recchia FM; Sternberg P
    Retina; 2011; 31(7):1316-22. PubMed ID: 21358364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of plasma protein binding on antimicrobial activity using time-killing curves.
    Zeitlinger MA; Sauermann R; Traunmüller F; Georgopoulos A; Müller M; Joukhadar C
    J Antimicrob Chemother; 2004 Nov; 54(5):876-80. PubMed ID: 15472003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of structural factors on the enhanced activity of moxifloxacin: a fluorescence and EPR spectroscopic study.
    Neves P; Leite A; Rangel M; de Castro B; Gameiro P
    Anal Bioanal Chem; 2007 Feb; 387(4):1543-52. PubMed ID: 17200861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a clinical Escherichia coli isolate expressing lux genes to study the antimicrobial pharmacodynamics of moxifloxacin.
    Salisbury V; Pfoestl A; Wiesinger-Mayr H; Lewis R; Bowker KE; MacGowan AP
    J Antimicrob Chemother; 1999 Jun; 43(6):829-32. PubMed ID: 10404323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the extent of protein binding of antibiotics by means of an automated continuous ultrafiltration method.
    Heinze A; Holzgrabe U
    Int J Pharm; 2006 Mar; 311(1-2):108-12. PubMed ID: 16431044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the interactions between fluoroquinolone antibiotics and lipids: a multitechnique approach.
    Bensikaddour H; Fa N; Burton I; Deleu M; Lins L; Schanck A; Brasseur R; Dufrêne YF; Goormaghtigh E; Mingeot-Leclercq MP
    Biophys J; 2008 Apr; 94(8):3035-46. PubMed ID: 18178657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
    Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic antimicrobial oligomers induce a composition-dependent topological transition in membranes.
    Yang L; Gordon VD; Mishra A; Som A; Purdy KR; Davis MA; Tew GN; Wong GC
    J Am Chem Soc; 2007 Oct; 129(40):12141-7. PubMed ID: 17880067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
    Kim SY; Lim JA; Choi JS; Choi EC; Joo CK
    Cornea; 2007 Jul; 26(6):720-5. PubMed ID: 17592324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual mechanism of bacterial lethality for a cationic sequence-random copolymer that mimics host-defense antimicrobial peptides.
    Epand RF; Mowery BP; Lee SE; Stahl SS; Lehrer RI; Gellman SH; Epand RM
    J Mol Biol; 2008 May; 379(1):38-50. PubMed ID: 18440552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin, ceftazidime, and moxifloxacin can be safely stored in single-use, polypropylene syringes.
    Armstrong BK; Mehta S; Kim SJ
    Retina; 2011 Nov; 31(10):2134-6. PubMed ID: 22027802
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
    Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
    J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.